Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$1.06 - $2.33 $205,855 - $452,492
-194,203 Reduced 14.59%
1,136,413 $1.24 Million
Q2 2023

Aug 11, 2023

BUY
$2.15 - $3.49 $1.41 Million - $2.29 Million
655,288 Added 97.03%
1,330,616 $3.05 Million
Q1 2023

May 12, 2023

BUY
$1.99 - $2.68 $505,710 - $681,057
254,126 Added 60.33%
675,328 $1.64 Million
Q4 2022

Feb 13, 2023

BUY
$1.8 - $2.56 $211,658 - $301,025
117,588 Added 38.73%
421,202 $804,000
Q3 2022

Nov 14, 2022

BUY
$1.94 - $3.43 $104,011 - $183,896
53,614 Added 21.45%
303,614 $729,000
Q2 2022

Aug 12, 2022

BUY
$1.31 - $2.69 $327,500 - $672,500
250,000 New
250,000 $465,000

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $134M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track This Portfolio

Track Parkman Healthcare Partners LLC Portfolio

Follow Parkman Healthcare Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkman Healthcare Partners LLC with notifications on news.